Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Juul

van den Reek

,

MD, PhD

Scientific Researcher
Radboud University Medical Center
Nijmegen
,
Netherlands
2022 Fellow
Councilor Since: March 8, 2024
IPC Councilor
Request an Update
Dr. Juul van den Reek works as an MD/epidemiologist at the Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands, where she combines research with patient care in the specialized psoriasis clinic. Her research interest focuses on clinical epidemiology and, more specifically, evaluating real-world data of patients treated with biologics for inflammatory diseases. She coordinates the BioCAPTURE registry, a national psoriasis registry for biologics, and the BeNeBio consortium, a Dutch-Belgium study on dose reduction of biologics for psoriasis. She is the medical advisor for the Dutch Psoriasis Foundation journal and a Dutch Psoriasis guideline committee member. Dr. van den Reek studied with IPC Board Member Joel Gelfand during her IPC Fellowship at his Philadelphia, Pennsylvania, United States clinic. She has been an IPC Councilor since March 2024.
Last Updated:
03/01/2024

Areas of Interest

Evaluation of effectiveness, drug survival, and safety of biologics for psoriasis in practice (real-world evidence), planetary health and psoriasis (sustainable choices in psoriasis care, including dose reduction of biologics and remote care), epidemiology of psoriasis and its comorbidities, and the Influence of gender on outcomes of psoriasis treatment

IPC Committees / Groups

Editorial Committee, Regional Development Task Force

Languages Spoken

Dutch, English

Involvement with Other Organization(s)

Dr. van den Reek is the Dutch Psoriasis Patient Federation journal advisor. The patient federation is closely involved in Dr. van den Reek’s studies as a patient advisor in her research. In 2017, she was a fellow of the National Psoriasis Foundation (NPF).
Recent publications

Featured

Video

Sex Differences in Psoriasis.

In this Take Ten with IPC video, Juul van den Reek and PhD candidate Liana Barenbrug discuss sex differences in…

Watch Video

PDF

A Report from the 34th Annual European Academy of Dermatology and Venereology (EADV) Congress.

Key takeaways from the 2025 EADV Congress in Paris, including the IPC Symposium on psoriasis, Free Communication…

View Report

PDF

The Global Burden of Pediatric Psoriasis: A Systematic Review.

View Report

PDF

IPC Psoriasis Disease Severity Reclassification: Update on Validity, Acceptance, and Implementation.

View Report

PDF

Investigation of the Applicability of Adult Definitions of Disease Severity for Psoriasis in a Pediatric Cohort: A…

Conflicts of interest Dr Al-Gawahiri carried out clinical trials for Janssen. All funding is not personal but goes to…

View Report

Video

The Epidemiology of Psoriasis.

In this Take Ten with IPC video, Dr. Juul van den Reek discusses the global epidemiology of psoriasis and highlights…

Watch Video

Blog

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Juul van den Reek, MD, PhD.

Learn about Juul van den Reek's experience as a 2022 participant in IPC's International Fellowship Program. In this…

Read More

PDF

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN).

Experts worldwide report on their experiences and deliver insight into the latest results and clinical studies. The…

View Report

Blog

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN)…

The 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) was held Wednesday, July 6 –…

Read More

Blog

Focus on Psoriasis: A Report from the 2021 Hybrid Gene to Clinic Congress.

The Psoriasis: from Gene to Clinic International Congress provides a forum for psoriasis experts from around the world…

Read More

PDF

Focus on Psoriasis – A Report from the 2021 Hybrid Gene to Clinic Congress.

View Report

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026